A coordinated Pan-European approach is essential for tackling the COVID-19 epidemic, and finding the most effective therapeutic solutions for this and any future outbreak. A number of ambitious EU-funded projects, EU-RESPONSE, RECOVER, and ECRAID-Prime share a joint coordination module that allows them to evaluate potential therapeutics for COVID-19, while avoiding duplications and maximizing the use of resources. Moreover, the EU-funded VACCELERATE project, focusing on vaccine platform trials is also linked to this coordination module.
The coordination module, comprises the Trial Coordination Board (TCB), the Joint Access Advisory Mechanism (JAAM) and the Adaptive Platform Trial Toolbox. Together, they ensure optimal coordination of trials in the EU and abroad, and provide a single entry point for new study arms in the European COVID-19 adaptive platform trials.
Overview of JAAM
How can new study drugs be evaluated in the existing European COVID-19 adaptive platform trials? The Joint Access Advisory Mechanism (JAAM) is the single access point for drug developers to propose new therapeutic solutions that can be evaluated in Phase II or Phase III trials. As an independent expert panel, the JAAM advises the EU-SolidAct, REMAP-CAP and ECRAID-Prime trials in Europe.See more
Overview of TCB
The Trial Coordination Board (TCB) gathers all key stakeholders involved in the implementation of trials and the successful integration of trial outcomes into clinical care. The TCB brings together four European COVID-19 adaptive platform trials (APT) along with other large trials from across the globe, policy makers and regulators, preclinical research experts, platform trial experts and more. It provides a forum for multilateral discussion and makes recommendations on the strategic development of the APTs.See more
The Adaptive Platform Trial Toolbox
This publicly available toolbox contains diverse guidelines, templates and references that can help in the design, implementation and management of complex adaptive platform trials (APT). Developed through multi-stakeholder collaborations and implemented within the COVID-19 APTs, these tools can be implemented in diverse disease areas.See more